The aim of this review article is to provide an update of the current literature on orbital tumors. The authors conducted a PubMed literature search of English language articles published between January 2014 and December 2016 using the following search items: orbit, tumors, lacrimal gland, lymphoma, hemangioma, lymphangioma. The authors included reviews, original articles, case series, and case reports with relevant new information. There is new information about the clinical spectrum of orbital tumors, capillary hemangioma, cavernous hemangioma, lymphangioma, orbital venous malformation, lacrimal gland tumors, and orbital lymphoma. This review highlights the current understanding, practice, and guidelines in the diagnosis and management of common tumors of the orbit.
O rbital tumors form a very broad and a diverse spectrum, which varies based on several demographic attributes and the referral pattern. Bonavolonta et al 1 analyzed 2480 orbital space occupying lesions in their retrospective review and found that the most common benign lesions were dermoid cyst (14%) and cavernous hemangioma (9%). In the same series, non-Hodgkin lymphoma was the most common malignant neoplasm (12%). Lacrimal gland lesions were benign in 64% (154/241), whereas the most common malignant tumor was adenoid cystic carcinoma (18%).
Hassan et al 2 found that the incidence of orbital tumors in the United States according to the Surveillance, Epidemiology, and End Results (SEER) database was 1.59 per million person years. They also reported a significant increase in the overall incidence of orbital, conjunctival, and lacrimal gland tumors, with lymphoma having the highest incidence.
Vascular Tumors and malformaTions
Orbital vascular malformations are currently classified as type 1 (no flow; lymphatic vascular malformations and venous lymphatic lesions), type 2 (venous flow; distensible/nondistensible venous vascular malformations and combined distensible venouslymphatic vascular malformations), and type 3 (arterial flow; arteriovenous malformation, cavernous hemangiomas, acquired arteriovenous shunts).
Orbital cavernous hemangioma (OCH) is the most common orbital tumor in adults and appears as a well-defined intraconal mass (Fig. 1) . McNab et al 3 studied the anatomical location and laterality of OCH in 104 patients. It was found that OCH has the propensity to occur in the intraconal space (87%) and lateral to the optic nerve (47%), a distribution that mirrors the distribution of small arteries and arterioles in the orbit.
In a study of OCH in 39 patients by Rootman et al, 4 it was found that 33% of patients presented with optic nerve dysfunction, with a best-corrected visual acuity of less than 20/40 in 28%. They found that 75% of the lesions were situated in the intraconal space, with optic nerve compression in 54%. They were also found to have a dynamic imaging pattern, which helps in differentiation from other intraconal tumors. Intraconal apical OCH poses a surgical challenge with poor visual outcome. Kloos et al 5 reported 4 cases of apical pear-shaped OCH, which were partially removed leading to postoperative hemorrhage and visual loss.
Goh et al 6 reported the outcome of gamma knife radiotherapy for apical lesions, including 3 cases of cavernous hemangioma and 2 cases of schwannoma. Each patient received 2000 cGy in fractionated doses leading to tumor shrinkage with average volume reduction of 76% and improved visual acuity. Application of gamma knife can avoid surgery-related complications in visually incapacitating benign orbital lesions situated in critical locations and thus not easily amenable to surgery.
A rare entity that requires special mention is intraosseous hemangioma. Although the pathogenesis of intraosseous hemangioma is unknown, these can occur in the orbit. Gupta et al 7 reported 6 cases of histopathologically confirmed intraosseous hemangioma with characteristic "honeycomb" pattern on computerized tomography images. Charles et al 8 reported a rare case of intramuscular hemangioma in the inferior oblique that was completely excised.
Lymphangioma of the orbit is a much discussed topic. It is classified as a type 1 vascular malformation according to the International Orbital Society. Although it is a benign entity, it may progress to severe globe displacement and cosmetic disfigurement. Lymphangioma can be both microcystic (≤1 cm) and macrocystic (≥1 cm). The management of lymphangioma poses a challenge due to the diffuse nature of the tumor and the associated bleeding. Surgical debulking has been attempted after intralesional injection of fibrin glue to solidify the lesion. Recently, Gooding et al 9 reported the use of intralesional bleomycin injection attributed to its sclerosing property on vascular endothelium and chemical pleurodesis. They injected a dose of 1 IU bleomycin in 1 mL and lignocaine in the ratio of 4:1 under direct visualization using a 23-gauge needle, with marked clinical improvement and only transient side effects. The amount injected was equivalent to the volume of the lesion, not exceeding 5 mL; the number of injections ranged from 1 to 6 (Fig. 2) .
The role of pingyangmycin was evaluated for low-flow orbital venous malformations by Jia et al. 10 Pingyangmycin belongs to the bleomycin family, also known as bleomycin A5, and was initially discovered in the Pingyang county of China. Of the 33 eyes treated, the majority were situated in the eyelid (52%), followed by the conjunctiva (27%), intraconal space (12%), glabella (6%), and inner canthus (3%). There was a mean decrease in volume of 84% (range, 28% to 100%) with a median number of 2 injections (range, 1 to 4) at an interval of 6 to 8 weeks, and there was no recurrence at a mean follow-up of 8 months. Similar results were reported by Yue et al 11 in 13 patients with venous malformation (n = 6), cavernous hemangioma (n = 6), and lymphangioma (n = 1). Injection was performed under direct observation in all except one and the mean dosage was 4.2 mg (range, 2 to 6 mg). The average reduction of volume was 70% without associated complications except for transient swelling.
It was found to be safe and effective.
Gandhi et al 12 reported the use of oral sildenafil (1 to 3 mg/kg) in divided doses in 2 children with orbital lymphangioma. The proposed mechanism is smooth muscle relaxation and collapse of cystic spaces of the lesion. Oral sildenafil is considered as a promising treatment in lymphangioma, although larger clinical trials may provide further details. Sclerotherapy with sodium tetradecyl sulphate is still considered as a management option in macrocystic lymphatic malformations. The outcome in 29 patients who underwent primary sclerotherapy (n = 18) and secondary treatment (n = 11) was encouraging with radiological resolution in 52%. 13 Infantile hemangioma is a congenital, self-limiting benign disease that is characterized by a proliferation phase and an involution phase. However, occasionally orbital infantile hemangioma may cause functional impairment as a result of proptosis, compressive optic neuropathy, and amblyopia. Levitt et al 14 reported 5 cases of orbital infantile hemangioma treated with oral propranolol (0.6 to 2.7 mg/kg). Maximal therapeutic effect is noticed during the proliferative phase (Fig. 3) . There was significant clinical and radiological improvement in all the cases.
Recently, Painter and Hildebrand 15 reported promising results of topical timolol 0.5% in 5 children with deep periocular infantile hemangioma.
Carotico-cavernous fistula (CCF) is an abnormal vascular communication leading to rapidly progressive orbital symptoms and signs. Often, the related ocular complications of CCF are mainly due to orbital congestion, vascular occlusion, and optic nerve compression. Various classifications of CCF are direct and indirect, high flow and low flow, spontaneous and traumatic. Angiographically, they are classified as anterior and posterior. Ocular involvement was found to be associated with anterior draining dural CCF. Tan et al 16 evaluated 45 patients with CCF. It was found that 18% had direct CCF and 82% were indirect. The majority (88%) had traumatic etiology in direct CCF, whereas hypertension (41%) and hyperlipidemia (46%) were the cause for indirect dural CCF. The major statistically significant risk factors associated with poor prognosis were the use of anticoagulants and visual acuity less than 6/60. figure 3 . Capillary hemangioma of infancy in the left eye with anterior orbital extension in the rapid proliferative phase in a 3-month-old child (A), which substantially involuted after oral propranolol 2 mg/kg per day in 2 divided doses for 3 months (B).
figure 4. A 52-year-old Indian female showing proptosis of the right eye with inferomedial globe displacement (A). The CT scan was suggestive of a well-defined large orbital mass occupying the superolateral orbit extending beyond the mid-orbit pushing the optic nerve medially. Lacrimal gland could not be seen separately (B, C). It was completely excised surgically and appeared as a well-encapsulated mass; it was diagnosed to be solitary fibrous tumor of the orbit on histopathology (D).
soliTary fibrous Tumor
Orbital solitary fibrous tumor, a rare spindle cell tumor, has been gaining attention recently. Clinically this may present as a well-defined intra-or extraconal mass simulating cavernous hemangioma, schwannoma, meningioma, or fibrous histiocytoma (Fig. 4) . Immunohistochemistry is the major diagnostic tool to differentiate it from aggressive hemagiopericytoma. It is found to exhibit strong immunoreactivity for CD34 (90-100%) and CD99 (70%). Le et al 17 reported 4 cases of orbital solitary fibrous tumor, which were indolent in nature without recurrence after complete excision. and lymphoproliferative disorders were the 2 most common lacrimal gland lesions in the series. Of the 69 patients, adenoid cystic carcinoma was found only in 1. Tang et al 18 retrospectively evaluated bilateral lacrimal gland diseases in 97 patients and found that idiopathic orbital inflammatory disease was the most common in etiology (30%) and lymphoma accounted for only 11%.
Dacryops and its pathogenesis is less understood. It is generally classified as palpebral, orbital, and Krause dacryops. Lam et al 19 in their recent series analyzed 5 specimens of excised dacryops histopathologically. They confirmed that cyst formation was due to chronic inflammation and immune response activating the local plasma cells to produce IgA that accumulates, resulting in osmotic effect and cyst formation.
Chawla et al 20 studied a case series of 66 epithelial tumors of the lacrimal gland that comprised benign pleomorphic adenoma in 76% (Fig. 5) and malignant in 24%. Adenoid cystic carcinoma (ACC) was the most common malignant tumor with a mean age at presentation of 32 years. Other malignant tumors included carcinoma ex-pleomorphic adenoma, lacrimal duct carcinoma, mucoepidermoid, and basal cell adenocarcinoma.
Gensheimer et al 21 reported the outcome of neutron radiotherapy in 11 eyes with ACC. By Kaplan-Meier analysis, 5-year local tumor control was 80%, disease-free survival was 61%, and overall survival was 90%. However, late recurrences and distant metastasis were a challenge. Of the 11 patients, 3 had local recurrence and 4 developed distant metastasis. The median radiation dose was 18.4 neutron Gy. Neutron radiotherapy carries the advantage of reduced dose and fractions of radiation delivery compared with conventional radiation. Holliday et al 22 reported the use of proton beam therapy in malignant epithelial tumors of the lacrimal gland with limited toxicity at a median radiation dose of 60 Gy. They limited the maximum corneal dose to 35 Gy with an eye deviation technique.
Tse et al
23 reported the long-term results of intra-arterial cytodestructive chemotherapy (IACC) with cisplatin and doxorubicin in ACC of lacrimal glands in 19 patients. In their study, IACC was administered in addition to orbital exenteration, chemoradiation, and systemic chemotherapy. They found an overall improved survival in patients receiving neoadjuvant IACC. Bell et al 24 found that KRAS, NRAS, and MET mutations were frequent in epithelial neoplasms in the lacrimal gland, especially in ACC, which can pave the way for newer targeted therapies. Of the 16 patients with ACC studied, 44% had these oncogenic mutations.
ocular adnexal lymphoma
Ocular adnexal lymphoma (OAL) is a malignant lymphoproliferative neoplasm involving the eyelid, conjunctiva, orbit, and lacrimal gland, comprising 30% of orbital tumors (Fig. 6) . It is often low-grade non-Hodgkin B-cell lymphoma. Of the OALs, extra-marginal zone lymphoma (EMZL) or mucosa-associated lymphoid tissue (MALT) lymphoma are most common (50% to 90%) and have better prognoses. Other types are follicular cell, mantle cell, diffuse large B-cell (DLBCL), and lymphoplasmacytic lymphoma. Rasmussen et al 25 performed a multicenter collaborative study on ocular adnexal follicular lymphoma (FL) from 6 ocular oncology centers around the world. Of the 98 patients included in the study, 70% had primary, 19% had associated systemic involvement, and 10% had ocular adnexal relapse. The most frequently involved sites were the lacrimal gland, conjunctiva, and orbit. On staging the disease, it was found that TNM staging was not consistent with disease progression and survival. Overall survival was 60% and 20% at 10 and 20 years, respectively. External beam radiotherapy alone as a treatment modality in FL showed favorable outcome with a disease-specific survival rate of 94% at a median dose rate of 26 Gy. In another study, Rasmussen et al 26 analyzed the clinicopathological aspects of OAL. Diffuse large B-cell lymphoma is an aggressive variant that accounts for 8-13% of lymphoma overall. They identified 34 patients with DLBCL with a median age of 78 years. Primary DLBCL occurred in 53% and orbit was the site of involvement. It was unilateral in 97%. The prognosis correlated with Ann Arbor classification; the higher the stage, the poorer the prognosis. Histopathologically, they were categorized as centroblastic and immunoblastic; immunoblastic had poorer prognosis in terms of overall survival. The overall 5-year survival rate was 20% in their study population, much lower than previously reported.
Until recently, OAL was staged according to the Ann Arbor classification system, originally designed for Hodgkin lymphoma. The recent introduction of the seventh edition of the American Joint Committee on Cancer (AJCC) TNM staging in OAL has been elaborately analyzed by various authors. Rath et al 27 analyzed 134 cases of OAL based on AJCC TNM staging and grouped the tumors according to laterality, along with nodal and systemic metastasis: group 0, unilateral OAL with no nodes or metastasis; group 2, either bilateral or positive nodes/metastasis; group 3, both bilateral OAL and positive nodes/metastasis. It was found that 10-year progression-free survival was 75%, 50%, and 0% in groups 0, 1, and 2, respectively.
Aronow et al 28 studied the current AJCC TNM staging in 63 patients with OAL. They found that although the TNM staging system was useful for precise characterization of local extent of tumor, it was not appropriate to predict recurrence or survival. In contrast, Sneigowski et al 29 in their evaluation of the prognostic significance of AJCC TNM staging of OAL in 82 patients found that higher staging was associated with decreased 5-year diseasefree survival. The prognosis and survival in OAL depends on the histologic subtype, laterality, and systemic involvement.
Takahashi et al 30 identified a high-resolution single nucleotide pleomorphism array that could detect choromosomal abnormality patterns in ocular adnexal lymphoma to differentiate it from benign lyphoproliferative disorders. Radiotherapy is the current standard of care in OAL locally, irrespective of the subtype, and is considered safe and effective. Woolf et al 31 showed excellent tumor control (100%) in 85 eyes with a median fractionated dose of 30 Gy. Local tumor control at 5 years was reported as 98% by Kharod et al 32 with 25.5 Gy in 44 patients. Rituximab, a chimeric monoclonal antibody directed against B-cell-specific CD20, has recently gained popularity in the treatment of non-Hodgkin B-cell lymphoma. Tuncer et al 33 evaluated the therapeutic efficacy of rituximab in 10 patients with OAL, figure 6 . A 40-year-old male presented with mild slowly increasing proptosis of the left eye for 1 year (A). CT scan shows an isodense mass molding around the eye (B) suggestive of orbital lymphoma, which was confirmed on incisional biopsy.
of which 4 had orbital involvement. Overall, complete response was achieved in 36% (n = 4) and the remainder required adjuvant radiotherapy for recurrence. In the presence of systemic involvement, it plays a major role.
orbiTal inVasion of basal cell carcinoma
Oral vismodegib, the hedgehog pathway inhibitor, has gained popularity recently in treating syndrome-associated and locally advanced/orbital basal cell carcinoma (BCC). There are case series and isolated case reports on the outcome and complications. Gill et al 34 evaluated the response and complications of 150 mg oral vismodegib in 7 patients with locally advanced BCC. At a mean treatment duration of 11 weeks (range, 4 to 16 weeks), 58% had 80-100% regression, 29% had less than 35% partial regression, and there was progression in 1 patient (14%). Of the 7 patients, 6 had adverse reactions including alopecia (29%), muscle cramps (29%), and dysgeusia (29%). Occurrence of new squamous cell carcinoma was observed in 2 patients after completion of treatment. Ozgur et al 35 recently reported 12 patients with locally advanced BCC and treatment outcome with vismodegib, of which 3 had complete response and 2 had progressive disease after complete response. The most common drug-related toxicities were muscle spasms (100%) and weight loss (83%). Although vismodegib is an accepted novel therapeutic option in BCC, side effects and long-term outcome need further validation.
conclusions
Knowledge of orbital diseases and their management has continued to evolve in the past year. We have valuable new information about orbital venous malformation, lacrimal gland tumors, and orbital lymphoma. Advanced basal cell carcinoma with orbital extension now has a conservative medical treatment.
